Aduro phase II halted for OS benefit in immunotherapy candidates
SAN FRANCISCO – Privately held Aduro Biotech Inc. reported that the Phase II trial of cancer immunotherapy candidates, CRS-207 and Gvax Pancreas, used in combination in metastatic pancreatic cancer was halted early on the recommendation of the data safety monitoring board and approval by the FDA after the study met the primary efficacy endpoint at a pre-planned interim analysis.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter